Jacqueline A. Maybin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jacqueline A. Maybin has a total of 159 co-authors. Here are the top co-authors by number of shared publications:
- Hilary O. D. Critchley
University of Edinburgh
21 shared publications - Philippa Tansy Kemp Saunders
University of Edinburgh
6 shared publications Catherine Walker
Centre for Reproductive Health, University of Edinburgh, Edinburgh, UK
5 shared publicationsHilary O. D. Critchley
Medical Research Council Centre for Reproductive Health, Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom
4 shared publicationsMarianne Watters
University of Edinburgh
4 shared publicationsNikhil Hirani
MRC Centre for Inflammation Research, The Queen’s Medical Research Centre, The University of Edinburgh, 47 Little France Crescent, Edinburgh, EH16 4TJ, Scotland
4 shared publications
Latest Publications
- Open Access
Life-course patterns of heavy menstrual bleeding and menstrual pain across multiple population-based cohorts
Background: Heavy menstrual bleeding (HMB) and menstrual pain (MP) are among the most common menstrual cycle related symptoms with substantial impacts on quality of life. Despite this, population-level evidence on their prevalence across the life course is scarce. Methods: We conducted descriptive analyses of six longitudinal population-based cohorts from the United Kingdom, United States, Norway, and Australia. We estimated cumulative prevalence (across all available timepoints) and age-specific point prevalence of HMB and MP. Cumulative prevalence estimates were stratified by sociodemographic factors, where data permitted. We also examined HMB and MP incidence in adolescent cohorts with repeated measurements. Findings: HMB and MP are commonly reported, with cumulative prevalence across all the cohorts and timepoints (i.e., ever reported) ranging from 36% to 89% for HMB and 46% to 72% for MP. In adolescence, MP (point-prevalence: 33% to 47%) is more commonly reported than HMB (16% to 24%), whereas in later ages (45 years and above), HMB (47% to 70%) is more prevalent than MP (24% to 40%). We found no consistent evidence that symptoms were more likely to co-occur than occur independently; patterns varied across life stages and cohorts. Symptoms were more common in those from lower socioeconomic backgrounds and minoritised ethnic groups. Incidence of both HMP and MP peaked in the years immediately following menarche. Interpretation: Most women experience heavy and/or painful periods at some point. MP is more common in adolescence and HMB in later reproductive life. Generating robust life-course evidence on menstrual symptom patterns is essential to inform clinical guidelines, reduce diagnostic delays, and address inequalities in menstrual health.
Open AccessLife-course patterns of heavy menstrual bleeding and menstrual pain across multiple population-based cohorts
Background: Heavy menstrual bleeding (HMB) and menstrual pain (MP) are among the most common menstrual cycle related symptoms with substantial impacts on quality of life. Despite this, population-level evidence on their prevalence across the life course is scarce. Methods: We conducted descriptive analyses of six longitudinal population-based cohorts from the United Kingdom, United States, Norway, and Australia. We estimated cumulative prevalence (across all available timepoints) and age-specific point prevalence of HMB and MP. Cumulative prevalence estimates were stratified by sociodemographic factors, where data permitted. We also examined HMB and MP incidence in adolescent cohorts with repeated measurements. Findings: HMB and MP are commonly reported, with cumulative prevalence across all the cohorts and timepoints (i.e., ever reported) ranging from 36% to 89% for HMB and 46% to 72% for MP. In adolescence, MP (point-prevalence: 33% to 47%) is more commonly reported than HMB (16% to 24%), whereas in later ages (45 years and above), HMB (47% to 70%) is more prevalent than MP (24% to 40%). We found no consistent evidence that symptoms were more likely to co-occur than occur independently; patterns varied across life stages and cohorts. Symptoms were more common in those from lower socioeconomic backgrounds and minoritised ethnic groups. Incidence of both HMP and MP peaked in the years immediately following menarche. Interpretation: Most women experience heavy and/or painful periods at some point. MP is more common in adolescence and HMB in later reproductive life. Generating robust life-course evidence on menstrual symptom patterns is essential to inform clinical guidelines, reduce diagnostic delays, and address inequalities in menstrual health.
- Open Access
- 26 March 2026
- Published by Springer Nature in BMC Public Health
- Vol. 26 (1) , 946
Menstrual experiences of adolescent girls in schools: recommendations for menstrual health education in England
Menstruation can negatively impact quality of life (QoL), particularly during adolescence. The stigma surrounding menstruation and lack of support and educ
- 26 March 2026
- Published by Springer Nature in BMC Public Health
- Vol. 26 (1) , 946
Open AccessMenstrual experiences of adolescent girls in schools: recommendations for menstrual health education in England
Menstruation can negatively impact quality of life (QoL), particularly during adolescence. The stigma surrounding menstruation and lack of support and educ
- Open Access
- 2 February 2026
- Published by Oxford University Press (OUP) in Reproduction
- Vol. 171 (3)
Could the untapped potential of the reproductive tract microbiome hold the key to tackling heavy menstrual bleeding?
In brief: This paper proposes that the reproductive microbiome is an underexplored determinant of menstrual health that may reshape our understanding of disorders such as heavy menstrual bleeding, which affects 1 in 3 women and significantly impacts quality of life. Abstract The well-studied role of the microbiome in gut physiology and pathology has led to revolutionary microbiome-targeted treatments, but the function of the reproductive tract microbiome is yet to be delineated. This underexplored avenue could shed light on historically neglected reproductive health symptoms such as heavy menstrual bleeding.
- 2 February 2026
- Published by Oxford University Press (OUP) in Reproduction
- Vol. 171 (3)
Open AccessCould the untapped potential of the reproductive tract microbiome hold the key to tackling heavy menstrual bleeding?
In brief: This paper proposes that the reproductive microbiome is an underexplored determinant of menstrual health that may reshape our understanding of disorders such as heavy menstrual bleeding, which affects 1 in 3 women and significantly impacts quality of life. Abstract The well-studied role of the microbiome in gut physiology and pathology has led to revolutionary microbiome-targeted treatments, but the function of the reproductive tract microbiome is yet to be delineated. This underexplored avenue could shed light on historically neglected reproductive health symptoms such as heavy menstrual bleeding.
- Open Access
- 16 September 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-19
The potential bidirectional relationship between long COVID and menstruation
Women have reported menstrual changes following SARS-CoV-2 infection and variation in long COVID symptoms across the menstrual cycle. We examined (i) whether COVID is linked to abnormal uterine bleeding (AUB), (ii) if long COVID symptoms vary with the menstrual cycle, and (iii) potential underlying mechanisms. Here we show long COVID was associated with AUB in a UK population. When compared to those never infected (n = 9423), long COVID participants (n = 1048) reported increased menstrual volume, duration and intermenstrual bleeding, while those who recovered from acute COVID (n = 1,716) reported minimal menstrual disruption. Long COVID symptoms examined in 54 women across the menstrual cycle revealed that severity was highest during the perimenstrual and proliferative phases. Serum and endometrial analysis revealed higher serum 5α-dihydrotestosterone and lower endometrial androgen receptors in long COVID versus no COVID. Other ovarian hormones showed no significant differences. Serum cytokine profiling indicated increased menstrual inflammation with long COVID and immune cell aggregates were observed in menstrual endometrium. In conclusion, long COVID was associated with AUB but not impaired ovarian function. Differences in peripheral and endometrial inflammation may contribute to AUB and long COVID symptom severity. We anticipate our findings will instigate exploration of new therapeutic strategies for women with long COVID.
- 16 September 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-19
Open AccessThe potential bidirectional relationship between long COVID and menstruation
Women have reported menstrual changes following SARS-CoV-2 infection and variation in long COVID symptoms across the menstrual cycle. We examined (i) whether COVID is linked to abnormal uterine bleeding (AUB), (ii) if long COVID symptoms vary with the menstrual cycle, and (iii) potential underlying mechanisms. Here we show long COVID was associated with AUB in a UK population. When compared to those never infected (n = 9423), long COVID participants (n = 1048) reported increased menstrual volume, duration and intermenstrual bleeding, while those who recovered from acute COVID (n = 1,716) reported minimal menstrual disruption. Long COVID symptoms examined in 54 women across the menstrual cycle revealed that severity was highest during the perimenstrual and proliferative phases. Serum and endometrial analysis revealed higher serum 5α-dihydrotestosterone and lower endometrial androgen receptors in long COVID versus no COVID. Other ovarian hormones showed no significant differences. Serum cytokine profiling indicated increased menstrual inflammation with long COVID and immune cell aggregates were observed in menstrual endometrium. In conclusion, long COVID was associated with AUB but not impaired ovarian function. Differences in peripheral and endometrial inflammation may contribute to AUB and long COVID symptom severity. We anticipate our findings will instigate exploration of new therapeutic strategies for women with long COVID.
- Open Access
- 9 January 2025
- Published by Springer Nature in Research Square
Long COVID and menstruation: bidirectional associations and potential mechanisms.
Women have reported both menstrual disruption following SARS-CoV-2 infection and that long COVID symptoms change across the menstrual cycle. Yet there is a lack of female-specific research on COVID and menstruation. We aimed to determine if (i) acute/long COVID is associated with abnormal uterine bleeding (AUB), (ii) long COVID symptoms vary across the menstrual cycle and (iii) the mechanisms underpinning any such associations. We reveal that long COVID was significantly associated with AUB in a UK population, with menstrual flow volume, duration, and intermenstrual bleeding reported as significantly increased (n=1048) compared to those who had never had COVID (n=9433). With acute COVID (n=2017), only menstrual volume was increased. Examination of long COVID symptoms in 54 women across the menstrual cycle revealed that symptom severity was increased during the peri-menstrual and proliferative phases. To determine the impact of long COVID on ovarian and endometrial function, we analysed blood serum and endometrial tissue from ten women with long COVID at three points of their menstrual cycle and age-matched samples collected pre-pandemic. Higher secretory phase serum 5α-dihydrotestosterone and lower menstrual and proliferative phase endometrial androgen receptor levels were found in those with long COVID versus controls. No other significant differences in ovarian sex steroid hormone levels were detected. Serum Anti-Mullerian Hormone levels were also comparable, consistent with no significant impact of long COVID on ovarian reserve. Serum cytokine profiling indicated more menstrual phase inflammation in those with long COVID versus controls and less inflammation during the proliferative phase. We detected menstrual endometrial immune cell aggregates in those with long COVID that may contribute to altered tissue inflammation and AUB. In conclusion, whilst long COVID was associated with menstrual disturbance, it reassuringly does not appear to significantly impact ovarian function. Differences in peripheral and endometrial inflammation may contribute to AUB and increase long COVID symptom severity at menstruation. We anticipate that these data from across the menstrual cycle will decrease the gender health gap in long COVID biomarker development and instigate further exploration of new therapeutic strategies for long COVID symptoms in women.
- 9 January 2025
- Published by Springer Nature in Research Square
Open AccessLong COVID and menstruation: bidirectional associations and potential mechanisms.
Women have reported both menstrual disruption following SARS-CoV-2 infection and that long COVID symptoms change across the menstrual cycle. Yet there is a lack of female-specific research on COVID and menstruation. We aimed to determine if (i) acute/long COVID is associated with abnormal uterine bleeding (AUB), (ii) long COVID symptoms vary across the menstrual cycle and (iii) the mechanisms underpinning any such associations. We reveal that long COVID was significantly associated with AUB in a UK population, with menstrual flow volume, duration, and intermenstrual bleeding reported as significantly increased (n=1048) compared to those who had never had COVID (n=9433). With acute COVID (n=2017), only menstrual volume was increased. Examination of long COVID symptoms in 54 women across the menstrual cycle revealed that symptom severity was increased during the peri-menstrual and proliferative phases. To determine the impact of long COVID on ovarian and endometrial function, we analysed blood serum and endometrial tissue from ten women with long COVID at three points of their menstrual cycle and age-matched samples collected pre-pandemic. Higher secretory phase serum 5α-dihydrotestosterone and lower menstrual and proliferative phase endometrial androgen receptor levels were found in those with long COVID versus controls. No other significant differences in ovarian sex steroid hormone levels were detected. Serum Anti-Mullerian Hormone levels were also comparable, consistent with no significant impact of long COVID on ovarian reserve. Serum cytokine profiling indicated more menstrual phase inflammation in those with long COVID versus controls and less inflammation during the proliferative phase. We detected menstrual endometrial immune cell aggregates in those with long COVID that may contribute to altered tissue inflammation and AUB. In conclusion, whilst long COVID was associated with menstrual disturbance, it reassuringly does not appear to significantly impact ovarian function. Differences in peripheral and endometrial inflammation may contribute to AUB and increase long COVID symptom severity at menstruation. We anticipate that these data from across the menstrual cycle will decrease the gender health gap in long COVID biomarker development and instigate further exploration of new therapeutic strategies for long COVID symptoms in women.
- Open Access
- 17 December 2024
- Published by Wiley in JCPP Advances
- Vol. 4 (4) , e12294
Camouflaging in neurodivergent and neurotypical girls at the transition to adolescence and its relationship to mental health: A participatory methods research study
Background: Adolescent girls with diagnoses of autism, ADHD and/or developmental coordination disorder (DCD) are at higher risk for mental health problems than boys with the same diagnoses and neurotypical girls. These girls are called neurodivergent here, though neurodivergence includes a broader range of diagnoses. One possible reason for this mental health disparity could be camouflaging, a coping strategy used more by girls. Camouflaging is when the individual pretends to be neurotypical, often involving substantial effort. This study aims to understand: (a) if the use of camouflaging has started by early adolescence, (b) how components of camouflaging (assimilation, masking, and compensation) present at this age, (c) if age predicts camouflaging and (d) what is the relationship with mental health.Methods: Participatory methods: A co‐production team of 15 adult neurodivergent women co‐produced the project and ranked camouflaging as their most important research theme.Main Study: Participants were 119 girls (70 neurodivergent, 49 neurotypical) aged 11–14 years. A transdiagnostic approach was adopted and the neurodivergent group had a diagnosis of autism, ADHD and/or DCD. Girls completed self‐report measures of camouflaging, anxiety, and depression in an online meeting with a researcher.Results: Neurodivergent and neurotypical girls presented similarly on two components of camouflaging namely masking and compensation, components related to presenting in a socially acceptable way and mimicry. Groups differed on the assimilation component, which is related to trying to fit in and involves the feelings of pretending/acting. Age had a medium effect on camouflaging with higher levels of camouflaging observed in older girls. Camouflaging scores strongly predicted anxiety and depression scores in both groups.Conclusions: The use of camouflaging, specifically assimilation, is evident in a transdiagnostic sample of 11–14 year old neurodivergent girls. Importantly, the strong relationship between camouflaging and poor mental health is present at this early age, substantiating the co‐production team's insights.
- 17 December 2024
- Published by Wiley in JCPP Advances
- Vol. 4 (4) , e12294
Open AccessCamouflaging in neurodivergent and neurotypical girls at the transition to adolescence and its relationship to mental health: A participatory methods research study
Background: Adolescent girls with diagnoses of autism, ADHD and/or developmental coordination disorder (DCD) are at higher risk for mental health problems than boys with the same diagnoses and neurotypical girls. These girls are called neurodivergent here, though neurodivergence includes a broader range of diagnoses. One possible reason for this mental health disparity could be camouflaging, a coping strategy used more by girls. Camouflaging is when the individual pretends to be neurotypical, often involving substantial effort. This study aims to understand: (a) if the use of camouflaging has started by early adolescence, (b) how components of camouflaging (assimilation, masking, and compensation) present at this age, (c) if age predicts camouflaging and (d) what is the relationship with mental health.Methods: Participatory methods: A co‐production team of 15 adult neurodivergent women co‐produced the project and ranked camouflaging as their most important research theme.Main Study: Participants were 119 girls (70 neurodivergent, 49 neurotypical) aged 11–14 years. A transdiagnostic approach was adopted and the neurodivergent group had a diagnosis of autism, ADHD and/or DCD. Girls completed self‐report measures of camouflaging, anxiety, and depression in an online meeting with a researcher.Results: Neurodivergent and neurotypical girls presented similarly on two components of camouflaging namely masking and compensation, components related to presenting in a socially acceptable way and mimicry. Groups differed on the assimilation component, which is related to trying to fit in and involves the feelings of pretending/acting. Age had a medium effect on camouflaging with higher levels of camouflaging observed in older girls. Camouflaging scores strongly predicted anxiety and depression scores in both groups.Conclusions: The use of camouflaging, specifically assimilation, is evident in a transdiagnostic sample of 11–14 year old neurodivergent girls. Importantly, the strong relationship between camouflaging and poor mental health is present at this early age, substantiating the co‐production team's insights.
- Open Access
- 11 September 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (4) , 1135-1147
Limiting Premenstrual Endometrial Hypoxia Inducible Factor 2 Alpha May Fine-Tune Endometrial Function at Menstruation
Context: Heavy menstrual bleeding (HMB) is common and debilitating, but the precise endometrial mechanisms causing increased menstrual blood loss (MBL) remain undefined. We have previously identified a role for hypoxia in endometrial repair following progesterone withdrawal. Objective: As hypoxia inducible factor 2 alpha (HIF2A) is known to alter vascular function in other tissues, we hypothezised that endometrial HIF2A is involved in premenstrual optimization of endometrial function during the secretory phase to limit MBL. Results: Women with objective HMB had higher endometrial HIF2A during the mid-secretory phase when compared to those with normal MBL (P = 0.0269). In a mouse model of simulated menses, genetic or pharmacological manipulation of HIF2A did not significantly affect endometrial breakdown/repair, volume of MBL or endometrial hypoxia. However, 88% of Hif2a heterozygote mice reached early-full repair by 24 hours vs only 65% of wild-type mice. Mean MBL was 0.39 μL (±0.67) in Hif2a heterozygote mice vs 0.98 μL (±0.79) in wild-type mice. Conversely, when we increased HIF2A before menstruation, 11% reached early repair by 8 hours vs 30% of vehicle-treated mice. Mean MBL was 2.61 μL (±1.10) in mice with HIF2A stabilization and 2.24 μL (±1.14) in vehicle-treated mice. These nonsignificant but consistent trends indicate that increased endometrial HIF2A may contribute to delayed endometrial repair and HMB. Conclusions: Increased HIF2A in the secretory endometrium is unlikely to be sufficient to account for the phenotype of HMB, but limitation of HIF2 levels may optimize endometrial function at menstruation.
- 11 September 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (4) , 1135-1147
Open AccessLimiting Premenstrual Endometrial Hypoxia Inducible Factor 2 Alpha May Fine-Tune Endometrial Function at Menstruation
Context: Heavy menstrual bleeding (HMB) is common and debilitating, but the precise endometrial mechanisms causing increased menstrual blood loss (MBL) remain undefined. We have previously identified a role for hypoxia in endometrial repair following progesterone withdrawal. Objective: As hypoxia inducible factor 2 alpha (HIF2A) is known to alter vascular function in other tissues, we hypothezised that endometrial HIF2A is involved in premenstrual optimization of endometrial function during the secretory phase to limit MBL. Results: Women with objective HMB had higher endometrial HIF2A during the mid-secretory phase when compared to those with normal MBL (P = 0.0269). In a mouse model of simulated menses, genetic or pharmacological manipulation of HIF2A did not significantly affect endometrial breakdown/repair, volume of MBL or endometrial hypoxia. However, 88% of Hif2a heterozygote mice reached early-full repair by 24 hours vs only 65% of wild-type mice. Mean MBL was 0.39 μL (±0.67) in Hif2a heterozygote mice vs 0.98 μL (±0.79) in wild-type mice. Conversely, when we increased HIF2A before menstruation, 11% reached early repair by 8 hours vs 30% of vehicle-treated mice. Mean MBL was 2.61 μL (±1.10) in mice with HIF2A stabilization and 2.24 μL (±1.14) in vehicle-treated mice. These nonsignificant but consistent trends indicate that increased endometrial HIF2A may contribute to delayed endometrial repair and HMB. Conclusions: Increased HIF2A in the secretory endometrium is unlikely to be sufficient to account for the phenotype of HMB, but limitation of HIF2 levels may optimize endometrial function at menstruation.
- Open Access
Consensus recommendations for measuring the impact of contraception on the menstrual cycle in contraceptive clinical trials
Objective We sought to develop consensus recommendations for improved measurement of contraceptive-induced menstrual changes (CIMCs) in contraceptive clinical trials to build upon previous standardization efforts. Study Design We undertook a virtual consensus-building process using a modified Delphi approach, incorporating aspects of Nominal Group Technique and the Jandhyala method. The process consisted of four half-day meetings, developing recommendations within five topical working groups, a series of consensus questionnaires to assess recommendation agreement on a 4-point Likert-like scale, and opportunities for input and feedback throughout the process. Recommendations required at least 75% consensus to be included. Results Our interdisciplinary group—from 26 organizations and 13 countries in five global regions across academia, nonprofit research organizations, the pharmaceutical industry, and funding agencies— developed 44 consensus recommendations. These included recommendations on standardization, patient-reported outcome measure development aligned with current regulatory guidance, trial design, protocol development, participant recruitment, data collection, data analysis, and areas for exploratory research. Seven recommendations were deemed a priority by over 85% of our group. Conclusion Using a formal consensus-building process, we reached high levels of agreement around recommendations for more standardized and patient-centered measurement of CIMCs in contraceptive clinical trials, now and in the future. Implications statement Consensus recommendations on measuring bleeding changes and related outcomes in contraceptive clinical trials can improve reporting of standardized, patient-centered outcomes in future product labeling. These improvements can enable providers to offer more relevant counseling on contraceptives and permit greater comparability and data synthesis across trials to inform clinical guidance.
Open AccessConsensus recommendations for measuring the impact of contraception on the menstrual cycle in contraceptive clinical trials
Objective We sought to develop consensus recommendations for improved measurement of contraceptive-induced menstrual changes (CIMCs) in contraceptive clinical trials to build upon previous standardization efforts. Study Design We undertook a virtual consensus-building process using a modified Delphi approach, incorporating aspects of Nominal Group Technique and the Jandhyala method. The process consisted of four half-day meetings, developing recommendations within five topical working groups, a series of consensus questionnaires to assess recommendation agreement on a 4-point Likert-like scale, and opportunities for input and feedback throughout the process. Recommendations required at least 75% consensus to be included. Results Our interdisciplinary group—from 26 organizations and 13 countries in five global regions across academia, nonprofit research organizations, the pharmaceutical industry, and funding agencies— developed 44 consensus recommendations. These included recommendations on standardization, patient-reported outcome measure development aligned with current regulatory guidance, trial design, protocol development, participant recruitment, data collection, data analysis, and areas for exploratory research. Seven recommendations were deemed a priority by over 85% of our group. Conclusion Using a formal consensus-building process, we reached high levels of agreement around recommendations for more standardized and patient-centered measurement of CIMCs in contraceptive clinical trials, now and in the future. Implications statement Consensus recommendations on measuring bleeding changes and related outcomes in contraceptive clinical trials can improve reporting of standardized, patient-centered outcomes in future product labeling. These improvements can enable providers to offer more relevant counseling on contraceptives and permit greater comparability and data synthesis across trials to inform clinical guidance.
- Open Access
- 19 February 2024
- Published by Portland Press Ltd. in Clinical Science
- Vol. 138 (4) , 153-171
COVID-19 and abnormal uterine bleeding: potential associations and mechanisms
The impact of COVID-19 on menstruation has received a high level of public and media interest. Despite this, uncertainty exists about the advice that women and people who menstruate should receive in relation to the expected impact of SARS-CoV-2 infection, long COVID or COVID-19 vaccination on menstruation. Furthermore, the mechanisms leading to these reported menstrual changes are poorly understood. This review evaluates the published literature on COVID-19 and its impact on menstrual bleeding, discussing the strengths and limitations of these studies. We present evidence consistent with SARS-CoV-2 infection and long COVID having an association with changes in menstrual bleeding parameters and that the impact of COVID vaccination on menstruation appears less significant. An overview of menstrual physiology and known causes of abnormal uterine bleeding (AUB) is provided before discussing potential mechanisms which may underpin the menstrual disturbance reported with COVID-19, highlighting areas for future scientific study. Finally, consideration is given to the effect that menstruation may have on COVID-19, including the impact of the ovarian sex hormones on acute COVID-19 severity and susceptibility and reported variation in long COVID symptoms across the menstrual cycle. Understanding the current evidence and addressing gaps in our knowledge in this area are essential to inform public health policy, direct the treatment of menstrual disturbance and facilitate development of new therapies, which may reduce the severity of COVID-19 and improve quality of life for those experiencing long COVID.
- 19 February 2024
- Published by Portland Press Ltd. in Clinical Science
- Vol. 138 (4) , 153-171
Open AccessCOVID-19 and abnormal uterine bleeding: potential associations and mechanisms
The impact of COVID-19 on menstruation has received a high level of public and media interest. Despite this, uncertainty exists about the advice that women and people who menstruate should receive in relation to the expected impact of SARS-CoV-2 infection, long COVID or COVID-19 vaccination on menstruation. Furthermore, the mechanisms leading to these reported menstrual changes are poorly understood. This review evaluates the published literature on COVID-19 and its impact on menstrual bleeding, discussing the strengths and limitations of these studies. We present evidence consistent with SARS-CoV-2 infection and long COVID having an association with changes in menstrual bleeding parameters and that the impact of COVID vaccination on menstruation appears less significant. An overview of menstrual physiology and known causes of abnormal uterine bleeding (AUB) is provided before discussing potential mechanisms which may underpin the menstrual disturbance reported with COVID-19, highlighting areas for future scientific study. Finally, consideration is given to the effect that menstruation may have on COVID-19, including the impact of the ovarian sex hormones on acute COVID-19 severity and susceptibility and reported variation in long COVID symptoms across the menstrual cycle. Understanding the current evidence and addressing gaps in our knowledge in this area are essential to inform public health policy, direct the treatment of menstrual disturbance and facilitate development of new therapies, which may reduce the severity of COVID-19 and improve quality of life for those experiencing long COVID.
- Open Access
- 29 April 2023
- Published by Oxford University Press (OUP) in Molecular Human Reproduction
- Vol. 29 (5)
Cyclic processes in the uterine tubes, endometrium, myometrium, and cervix: pathways and perturbations
This review leads the 2023 Call for Papers in MHR: ‘Cyclical function of the female reproductive tract’ and will outline the complex and fascinating changes that take place in the reproductive tract during the menstrual cycle. We will also explore associated reproductive tract abnormalities that impact or are impacted by the menstrual cycle. Between menarche and menopause, women and people who menstruate living in high-income countries can expect to experience ∼450 menstrual cycles. The primary function of the menstrual cycle is to prepare the reproductive system for pregnancy in the event of fertilization. In the absence of pregnancy, ovarian hormone levels fall, triggering the end of the menstrual cycle and onset of menstruation. We have chosen to exclude the ovaries and focus on the other structures that make up the reproductive tract: uterine tubes, endometrium, myometrium, and cervix, which also functionally change in response to fluctuations in ovarian hormone production across the menstrual cycle. This inaugural paper for the 2023 MHR special collection will discuss our current understanding of the normal physiological processes involved in uterine cyclicity (limited specifically to the uterine tubes, endometrium, myometrium, and cervix) in humans, and other mammals where relevant. We will emphasize where knowledge gaps exist and highlight the impact that reproductive tract and uterine cycle perturbations have on health and fertility.
- 29 April 2023
- Published by Oxford University Press (OUP) in Molecular Human Reproduction
- Vol. 29 (5)
Open AccessCyclic processes in the uterine tubes, endometrium, myometrium, and cervix: pathways and perturbations
This review leads the 2023 Call for Papers in MHR: ‘Cyclical function of the female reproductive tract’ and will outline the complex and fascinating changes that take place in the reproductive tract during the menstrual cycle. We will also explore associated reproductive tract abnormalities that impact or are impacted by the menstrual cycle. Between menarche and menopause, women and people who menstruate living in high-income countries can expect to experience ∼450 menstrual cycles. The primary function of the menstrual cycle is to prepare the reproductive system for pregnancy in the event of fertilization. In the absence of pregnancy, ovarian hormone levels fall, triggering the end of the menstrual cycle and onset of menstruation. We have chosen to exclude the ovaries and focus on the other structures that make up the reproductive tract: uterine tubes, endometrium, myometrium, and cervix, which also functionally change in response to fluctuations in ovarian hormone production across the menstrual cycle. This inaugural paper for the 2023 MHR special collection will discuss our current understanding of the normal physiological processes involved in uterine cyclicity (limited specifically to the uterine tubes, endometrium, myometrium, and cervix) in humans, and other mammals where relevant. We will emphasize where knowledge gaps exist and highlight the impact that reproductive tract and uterine cycle perturbations have on health and fertility.